Compare TIL & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIL | NEPH |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 40.1M |
| IPO Year | 2021 | 2004 |
| Metric | TIL | NEPH |
|---|---|---|
| Price | $7.40 | $4.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $125.00 | $6.00 |
| AVG Volume (30 Days) | 8.0K | ★ 15.6K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.06 | ★ 1000.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $38.54 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $5.67 | $2.66 |
| 52 Week High | $33.83 | $6.42 |
| Indicator | TIL | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 66.05 |
| Support Level | $6.91 | $4.44 |
| Resistance Level | $7.50 | $4.85 |
| Average True Range (ATR) | 0.19 | 0.36 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 85.35 | 81.84 |
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.